Proceedings · Session S-898 · filed November 19, 2026

Translational ScienceSession paper

FDA rejects ivonescimab, clears Roche's Wilserdly in November oncology sweep

FDA rejects ivonescimab over missing survival data while approving Roche's Wilserdly; cretostimogene cuts recurrence risk 68%, and Lilly, Boehringer and Dren Bio commit billions.

By Amara Osei5 min read1,005 words

Summary

  • FDA complete response letter blocks ivonescimab in NSCLC without statistically significant overall survival benefit
  • Cretostimogene cut bladder cancer recurrence risk 68% after 17 months; second BLA expected Q2 2027
  • Dren Bio raised $350 million; Boehringer's SBP deal carries up to $7 billion in milestones; Lilly-Stipple up to $5.9 billion
  • FDA approved Roche's Wilserdly (giredestrant) for ESR1-mutated advanced breast cancer
  • Sellas' GPS vaccine cut death risk 41% in a 126-patient phase 3 AML trial
Oncology biotech news: Key moves to watch in November 2026
FigureOncology biotech news: Key moves to watch in November 2026 — Kost9n4 / pixabay

By Amara Osei

The U.S. Food and Drug Administration issued a complete response letter against Summit Therapeutics' ivonescimab while approving Roche's Wilserdly in the same month — a split verdict that sharpens the agency's demand for survival data, not just progression-free gains. The two decisions headline a November cycle that also delivered a 68% recurrence-risk reduction in bladder cancer, a $350 million private round, and licensing packages totaling more than $7 billion in potential milestones. Here is what the numbers do and do not support.

What does the ivonescimab rejection change?

The FDA refused to approve the PD-1xVEGF bispecific in combination with platinum chemotherapy for locally advanced or metastatic non-small cell lung cancer after prior EGFR tyrosine kinase inhibitor therapy. The agency's reasoning is unusually explicit: substantial evidence of effectiveness is not established without a statistically significant overall survival improvement, and a progression-free survival benefit alone does not carry a positive benefit-risk profile.

The setback lands on a class investors have treated as a near-term commercial story. Summit's chairman and co-CEO Robert W. Duggan pushed back in a press release: "With five positive phase 3 studies between Summit and Akeso, nothing changes with respect to our ever-growing belief in the opportunity for ivonescimab and our determination to advance ivonescimab's development." The company continues multiregional phase 2 and 3 trials in NSCLC, colorectal cancer, urothelial carcinoma, and renal cell carcinoma. What remains unstated is whether any of those trials are powered for overall survival as a primary endpoint.

How strong is cretostimogene's phase 3 result?

CG Oncology's intravesically delivered oncolytic immunotherapy cretostimogene grenadenorepvec met its primary endpoint in intermediate-risk and high-grade non-muscle invasive bladder cancer, cutting the risk of recurrence by 68% versus control after 17 months of follow-up. The company frames the candidate as a possible "backbone" therapy across multiple settings.

The regulatory path is slower than the data. CG Oncology has already filed a BLA in BCG-unresponsive disease, but timelines have slipped; on FDA feedback, the company is broadening that submission to cover both CIS and high-grade papillary-only disease, with completion anticipated in March 2027. The new phase 3 data will support a second BLA, anticipated in Q2 2027. Notably, no FDA-approved adjuvant option currently exists for this patient population — a genuine gap, provided the 68% figure holds up in full datasets.

Who is funding what?

Dren Bio closed an oversubscribed $350 million private financing to carry its CD94-targeting monoclonal antibody dibotatug through late-stage development, regulatory submission, and a planned launch. The antibody selectively depletes pathogenic cytotoxic cells while sparing the broader immune system, and targets two rare diseases: cytotoxic T-cell lymphoma and large granular lymphocytic leukemia. Neither has an approved therapy.

The company reports high overall and complete response rates in relapsed/refractory disease across a phase 1/2 study of more than 300 dosed patients, with what it calls a favorable safety profile. Those figures come from company-reported maturing data, not a peer-reviewed readout — a distinction portfolio teams should keep in view.

Where is Lilly placing its capital?

Eli Lilly moved twice. It agreed to acquire Calytrix Bio for up to $1.5 billion, gaining a biparatopic antibody against mutant calreticulin-driven essential thrombocythemia and myelofibrosis. Current therapies for both disorders largely manage symptoms, so a drug designed for pan-mutant disease-modifying activity with a long-term safety profile would address the driver mutations directly.

Separately, Lilly signed a multi-target research and license deal with Stipple Bio, whose Pointillist Platform identifies tumor-specific cell surface epitope binders intended to raise efficacy while limiting on-target, off-tumor toxicity. Stipple receives an upfront payment plus equity and is eligible for up to $5.9 billion in milestones; Lilly takes exclusive worldwide rights to resulting products.

Boehringer Ingelheim made a parallel bet, inking a multi-program option and license agreement with SBP Group covering six preclinical biologic programs built on antibody-drug conjugate and T-cell engager technologies. Five programs come from SBP subsidiary LaNova Medicines and one from Beijing Tide Pharmaceutical. SBP receives $358 million upfront and near-term, with up to $7 billion in potential option, development, regulatory, and commercial milestones. Boehringer's options cover ex-China rights for four programs and worldwide rights for two — but only after agreed clinical milestones are reached, meaning SBP shareholders carry the early development risk.

Which approvals and survival data stand out?

The FDA approved Roche's Wilserdly (giredestrant), an oral SERD, for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. Roche says it is the first next-generation all-oral SERD combination to beat standard endocrine therapy head-to-head in a phase 3 trial after CDK4/6 inhibitors, in combination with everolimus. The unmet need is quantified: up to 40% of patients with HR-positive metastatic breast cancer develop ESR1 mutations driving resistance. An FDA decision on the adjuvant setting is expected by end of November; approval would make it the first SERD cleared for both adjuvant and advanced disease.

Sellas Life Sciences, meanwhile, reported that its off-the-shelf vaccine galinpepimut-S met its primary endpoint in a 126-patient phase 3 trial in acute myeloid leukemia, cutting the risk of death by 41% — median overall survival of 24 months versus 14.7 months on best available treatment. The vaccine trains immunity against WT1-bearing residual leukemia cells. President and CEO Angelos Stergiou said the company looks "forward to engaging with the FDA to discuss the results and the regulatory path forward, with the goal of making this therapy available to patients as rapidly as possible." A 126-patient study is modest for a survival claim, and no filing timeline was given.

The next test for these assets arrives quickly: three of them face FDA interactions within roughly six months, with CG Oncology's March 2027 BLA completion the first concrete deadline on the calendar.

via LABIOTECH.eu (Source)

Filed under

  • oncology-drug-development
  • fda-regulation
  • phase-3-trials
  • biotech-funding
  • pharma-licensing
Share this article:

More from Amara Osei

Amara Osei

Show full bio

News editor covering money, funding and market shifts around research and development at Hypothesis Wire.

254 articles

References

  1. Neladalkib Wins Accelerated Approval: 49% ORR After Alectinib
  2. Cretostimogene Cuts Bladder Cancer Recurrence Risk 68% in Phase 3
  3. Cancer Cell publishes sac-TMT plus osimertinib translational data
  4. FDA Clears Two AstraZeneca Biologics in Four Days
  5. FDA approval and four licensing deals anchor PharmTech roundup

« Previous article